Topics

"Based Absolute Antibody Partners with Recombinant Antibody Network" Drugs and Medication Database

07:24 EST 21st January 2020 | BioPortfolio

Here are the most relevant "Based Absolute Antibody Partners with Recombinant Antibody Network" Drugs and Medications that we have found in our database.

More Information about "Based Absolute Antibody Partners with Recombinant Antibody Network" on BioPortfolio

We have published hundreds of Based Absolute Antibody Partners with Recombinant Antibody Network news stories on BioPortfolio along with dozens of Based Absolute Antibody Partners with Recombinant Antibody Network Clinical Trials and PubMed Articles about Based Absolute Antibody Partners with Recombinant Antibody Network for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Based Absolute Antibody Partners with Recombinant Antibody Network Companies in our database. You can also find out about relevant Based Absolute Antibody Partners with Recombinant Antibody Network Drugs and Medications on this site too.

Showing "Based Absolute Antibody Partners with Recombinant Antibody Network" Drugs and Medications 1–25 of 306

Probably Relevant

Tysabri [biogen inc.]

These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI.TYSABRI (natalizumab) injection, for intravenous useInitial U.S. Approval: 2004

Possibly Relevant

Aimovig [amgen inc]

These highlights do not include all the information needed to use AIMOVIG safely and effectively. See full prescribing information for AIMOVIG. AIMOVIG (erenumab-aooe) injection, for subcutaneous use Initial U.S. Approval: 2018

Campath [genzyme corporation]

These highlights do not include all the information needed to use CAMPATH safely and effectively. See full prescribing information for CAMPATH. CAMPATH (alemtuzumab) Injection for intravenous useInitial U.S. Approval: 2001

Zinplava [merck sharp & dohme corp.]

These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA™ (bezlotoxumab) injection, for intravenous use Initial U.S. Approval: 2016

Emgality [eli lilly and company]

These highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY.EMGALITY (galcanezumab-gnlm) injection, for subcutaneous useInitial U.S. Approval: 2018

Ajovy [teva pharmaceuticals usa, inc.]

These highlights do not include all the information needed to use AJOVY safely and effectively. See full prescribing information for AJOVY.AJOVY (fremanezumab-vfrm) injection, for subcutaneous useInitial U.S. Approval: 2018

Cerezyme [genzyme corporation]

NA

Fasenra [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use FASENRA safely and effectively. See full prescribing information for FASENRA.FASENRA (benralizumab) injection, for subcutaneous useInitial U.S. Approval: 2017

Byetta [physicians total care, inc.]

These highlights do not include all the information needed to use BYETTA safely and effectively. See full prescribing information for BYETTA. BYETTA (exenatide) Injection Initial U.S. Approval: 2005

Takhzyro [dyax corp.]

These highlights do not include all the information needed to use TAKHZYRO™ safely and effectively. See full prescribing information for TAKHZYRO™. TAKHZYRO™ (lanadelumab-flyo) injection, for subcutaneous use.Initial U.S. Approval: 2018.

Sovaldi [gilead sciences, inc.]

These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI(sofosbuvir) tablets, for oral use Initial U.S. Approval: 2013

Sovaldi access [gilead sciences, inc.]

These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. GILEAD ACCESS PROGRAM SOVALDI™ (sofosbuvir) tablets, for oral use Initial U.S. Approval: 2013

Oxygen [respiratory care partners, inc]

Oxygen

Adlyxin [sanofi-aventis u.s. llc]

These highlights do not include all the information needed to use ADLYXIN safely and effectively. See full prescribing information for ADLYXIN. ADLYXIN (lixisenatide) injection, for subcutaneous use Initial U.S. Approval: 2016

Lartruvo [eli lilly and company]

These highlights do not include all the information needed to use LARTRUVO safely and effectively. See full prescribing information for LARTRUVO.LARTRUVO (olaratumab) injection, for intravenous useInitial U.S. Approval: 2016

Recothrom [mallinckrodt hospital products inc.]

These highlights do not include all the information needed to use RECOTHROM safely and effectively. See full prescribing information for RECOTHROM. RECOTHROM Thrombin topical (Recombinant) Lyophilized Powder for Solution - For Topical Use Only Initial U.S

Recothrom [baxter healthcare corporation]

These highlights do not include all the information needed to use RECOTHROM safely and effectively. See full prescribing information for RECOTHROM. RECOTHROM Thrombin topical (Recombinant) Lyophilized Powder for Solution – For Topical Use Only Initial U

Ultomiris [alexion pharmaceuticals inc.]

These highlights do not include all the information needed to use ULTOMIRIS™ safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS™ (ravulizumab-cwvz) injection, for intravenous useInitial U.S. Approval: 2018

Kineret [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use KINERET safely and effectively. See full prescribing information for KINERET. KINERET® (anakinra) injection, for subcutaneous useInitial U.S. Approval: 2001

Harvoni [gilead sciences, inc]

These highlights do not include all the information needed to use HARVONI safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014

Sylvant [janssen biotech, inc.]

These highlights do not include all the information needed to use SYLVANT safely and effectively. See full prescribing information for SYLVANT. SYLVANT (siltuximab) for injection, for intravenous use Initial U.S. Approval: 2014

Harvoni access [gilead sciences, inc]

These highlights do not include all the information needed to use HARVONI™ safely and effectively. See full prescribing information for HARVONI. HARVONI (ledipasvir and sofosbuvir) tablets, for oral use GILEAD ACCESS PROGRAM Initial U.S. Approval: 2014

Moderiba [abbvie inc.]

These highlights do not include all the information needed to use Moderiba (ribavirin, USP) safely and effectively. See full prescribing information for Moderiba (ribavirin, USP). Moderiba (ribavirin, USP) Tablets for oral useInitial U.S. Approval: 2002

Praxbind [boehringer ingelheim pharmaceuticals, inc.]

These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015

Ledipasvir and sofosbuvir [asegua therapeutics llc]

These highlights do not include all the information needed to use LEDIPASVIR and SOFOSBUVIR TABLETS safely and effectively. See full prescribing information for LEDIPASVIR and SOFOSBUVIR TABLETS. LEDIPASVIR and SOFOSBUVIR tablets, for oral useInitial U.S.



Quick Search